536 related articles for article (PubMed ID: 29598451)
1. Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis.
Coornaert I; Hofmans S; Devisscher L; Augustyns K; Van Der Veken P; De Meyer GRY; Martinet W
Expert Opin Drug Discov; 2018 Jun; 13(6):477-488. PubMed ID: 29598451
[TBL] [Abstract][Full Text] [Related]
2. Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis.
Rasheed A; Robichaud S; Nguyen MA; Geoffrion M; Wyatt H; Cottee ML; Dennison T; Pietrangelo A; Lee R; Lagace TA; Ouimet M; Rayner KJ
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1155-1167. PubMed ID: 32212851
[TBL] [Abstract][Full Text] [Related]
3. The neurotoxicant PCB-95 by increasing the neuronal transcriptional repressor REST down-regulates caspase-8 and increases Ripk1, Ripk3 and MLKL expression determining necroptotic neuronal death.
Guida N; Laudati G; Serani A; Mascolo L; Molinaro P; Montuori P; Di Renzo G; Canzoniero LMT; Formisano L
Biochem Pharmacol; 2017 Oct; 142():229-241. PubMed ID: 28676433
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
5. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Newton K; Dugger DL; Maltzman A; Greve JM; Hedehus M; Martin-McNulty B; Carano RA; Cao TC; van Bruggen N; Bernstein L; Lee WP; Wu X; DeVoss J; Zhang J; Jeet S; Peng I; McKenzie BS; Roose-Girma M; Caplazi P; Diehl L; Webster JD; Vucic D
Cell Death Differ; 2016 Sep; 23(9):1565-76. PubMed ID: 27177019
[TBL] [Abstract][Full Text] [Related]
6. RIPK1/RIPK3/MLKL-mediated necroptosis contributes to compression-induced rat nucleus pulposus cells death.
Chen S; Lv X; Hu B; Shao Z; Wang B; Ma K; Lin H; Cui M
Apoptosis; 2017 May; 22(5):626-638. PubMed ID: 28289909
[TBL] [Abstract][Full Text] [Related]
7. Necroptosis in development and diseases.
Shan B; Pan H; Najafov A; Yuan J
Genes Dev; 2018 Mar; 32(5-6):327-340. PubMed ID: 29593066
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
9. FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
Wang Z; Feng J; Yu J; Chen G
J Cell Sci; 2019 May; 132(10):. PubMed ID: 31028177
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation.
Duan X; Liu X; Liu N; Huang Y; Jin Z; Zhang S; Ming Z; Chen H
Cell Death Dis; 2020 Feb; 11(2):134. PubMed ID: 32075957
[TBL] [Abstract][Full Text] [Related]
11. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
Fauster A; Rebsamen M; Huber KV; Bigenzahn JW; Stukalov A; Lardeau CH; Scorzoni S; Bruckner M; Gridling M; Parapatics K; Colinge J; Bennett KL; Kubicek S; Krautwald S; Linkermann A; Superti-Furga G
Cell Death Dis; 2015 May; 6(5):e1767. PubMed ID: 25996294
[TBL] [Abstract][Full Text] [Related]
12. RIPK1-RIPK3-MLKL-Associated Necroptosis Drives
Barbosa LA; Fiuza PP; Borges LJ; Rolim FA; Andrade MB; Luz NF; Quintela-Carvalho G; Lima JB; Almeida RP; Chan FK; Bozza MT; Borges VM; Prates DB
Front Immunol; 2018; 9():1818. PubMed ID: 30154785
[TBL] [Abstract][Full Text] [Related]
13. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis.
Rodriguez DA; Weinlich R; Brown S; Guy C; Fitzgerald P; Dillon CP; Oberst A; Quarato G; Low J; Cripps JG; Chen T; Green DR
Cell Death Differ; 2016 Jan; 23(1):76-88. PubMed ID: 26024392
[TBL] [Abstract][Full Text] [Related]
14. 24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Vo DK; Urano Y; Takabe W; Saito Y; Noguchi N
Steroids; 2015 Jul; 99(Pt B):230-7. PubMed ID: 25697054
[TBL] [Abstract][Full Text] [Related]
15. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis.
Karunakaran D; Geoffrion M; Wei L; Gan W; Richards L; Shangari P; DeKemp EM; Beanlands RA; Perisic L; Maegdefessel L; Hedin U; Sad S; Guo L; Kolodgie FD; Virmani R; Ruddy T; Rayner KJ
Sci Adv; 2016 Jul; 2(7):e1600224. PubMed ID: 27532042
[TBL] [Abstract][Full Text] [Related]
16. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
Kearney CJ; Cullen SP; Clancy D; Martin SJ
FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
[TBL] [Abstract][Full Text] [Related]
17. RIPK1 inhibits ZBP1-driven necroptosis during development.
Newton K; Wickliffe KE; Maltzman A; Dugger DL; Strasser A; Pham VC; Lill JR; Roose-Girma M; Warming S; Solon M; Ngu H; Webster JD; Dixit VM
Nature; 2016 Dec; 540(7631):129-133. PubMed ID: 27819682
[TBL] [Abstract][Full Text] [Related]
18.
Karunakaran D; Nguyen MA; Geoffrion M; Vreeken D; Lister Z; Cheng HS; Otte N; Essebier P; Wyatt H; Kandiah JW; Jung R; Alenghat FJ; Mompeon A; Lee R; Pan C; Gordon E; Rasheed A; Lusis AJ; Liu P; Matic LP; Hedin U; Fish JE; Guo L; Kolodgie F; Virmani R; van Gils JM; Rayner KJ
Circulation; 2021 Jan; 143(2):163-177. PubMed ID: 33222501
[TBL] [Abstract][Full Text] [Related]
19. Necroptosis inhibitors: mechanisms of action and therapeutic potential.
Zhou Y; Cai Z; Zhai Y; Yu J; He Q; He Y; Jitkaew S; Cai Z
Apoptosis; 2024 Feb; 29(1-2):22-44. PubMed ID: 38001341
[TBL] [Abstract][Full Text] [Related]
20. The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL.
Jacobsen AV; Pierotti CL; Lowes KN; Au AE; Zhang Y; Etemadi N; Fitzgibbon C; Kersten WJA; Samson AL; van Delft MF; Huang DCS; Sabroux HJ; Lessene G; Silke J; Murphy JM
Cell Death Dis; 2022 Apr; 13(4):291. PubMed ID: 35365636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
